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Abstract Congenital disorders of glycosylation (CDG)
form a group of metabolic disorders caused by deficient
glycosylation of proteins and/or lipids. Isoelectric focusing
(IEF) of serum transferrin is the most common screening
method to detect abnormalities of protein N-glycosylation.
On the basis of the IEF profile, patients can be grouped into
CDG type I or CDG type II. Several protein variants of
transferrin are known that result in a shift in isoelectric
point (pI). In some cases, these protein variants co-migrate
withtransferrin glycoforms, which complicates interpretation.
In two patients with abnormal serum transferrin IEF profiles,
neuraminidase digestion and subsequent IEF showed profiles
suggestiveofthe diagnosis ofCDG typeI.Massspectrometry
of tryptic peptides of immunopurified transferrin, however,
revealed a novel mutation at the N-glycan attachment site. In
case 1, a peptide with mutation p.Asn630Thr in the 2nd
glycosylation site was identified, resulting in an additional
bandatdisialotransferrinpositiononIEF.Afterneuraminidase
digestion, a single band was found at the asialotransferrin
position, indistinguishable from CDG type I patients. In case
2, a peptide with mutation p.Asn432His was found. These
results show the use of mass spectrometry of transferrin
peptides in the diagnostic track of CDG type I.
Abbreviations
CDG Congenital disorders of glycosylation
IEF Isoelectric focusing
LC-MS Liquid chromatography mass spectrometry
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Introduction
Congenital disorders of glycosylation (CDG) comprise a
group of rare inherited metabolic disorders caused by
deficient glycosylation of proteins and/or lipids. For N-
glycan biosynthesis, a lipid-linked oligosaccharide is
synthesized in the endoplasmatic reticulum, and transferred
en bloc to a nascent protein. N-glycans are exclusively
transferred to an asparagine in the consensus sequence Asn-
Xxx-Ser/Thr, where Xxx is any amino acid except proline.
The glycosylated protein is then transferred to the Golgi for
further processing of the glycans. Defects in the biosynthesis
and transfer of the lipid-linked oligosaccharide result in the
loss of whole N-glycans on glycoproteins, resulting in a CDG
type I (CDG-I).
Diagnostic screening of CDG is performed by isoelectric
focusing (IEF) of transferrin. In its most abundant form,
this serum glycoprotein carries two complex N-glycans
attached to Asn432 and Asn630. Each N-glycan is
terminated by two negatively charged sialic acids. Defects
in the biosynthesis of N-glycans in the endoplasmatic
reticulum cause a loss of one or two complete N-glycans,
resulting in a typical IEF pattern of CDG-I, characterized
by increased asialo- and disialotransferrin bands, and
decreased tetrasialotransferrin. Secondary causes of hypo-
glycosylation such as galactosemia or fructosemia may
cause an identical pattern and therefore must be excluded.
Several transferrin protein polymorphisms result in a
shifted IEF pattern, caused by pI differences of the
polypeptide chain (Fujita et al. 1985; Kamboh and Ferrell
1987). Variant TF C is the most common form of
transferrin, the anodic variant B and cathodic variant D
are less common. In particular, heterozygous combinations
of C and D variants may lead to misinterpretation in CDG
diagnosis (Fujita et al. 1985; Marklova and Albahri 2009).
Nevertheless, these polymorphisms can be identified by
neuraminidase treatment of serum, resulting in an IEF pattern
with two distinct asialotransferrin bands (Fig. 1,l a n e5 ) .
To improve diagnostics of CDG, mass spectrometric
methods for glycoprotein analysis are being developed
because of their higher sensitivity and specificity (Hahn et
al. 2006; Lacey et al. 2001; Wada 2006; Wada 2007). Liquid
chromatography-mass spectrometry (LC-MS) of immuno-
purified transferrin was proven to be a sensitive screening
method for CDG-I, showing distinct peaks for fully
glycosylated transferrin, and transferrin lacking one or
twooligosaccharidechains(Bunkenborgetal.2004; Hulsmeier
et al. 2007; Lacey et al. 2001;W a d ae ta l .1992). For CDG
type II with abnormal processing of glycans, analysis of
enzymatically removed glycans can be diagnostic (Guillard
et al. 2011).
Here, we present the application of MS of transferrin
peptides in the diagnosis of CDG and reveal two novel
transferrin mutations in the N-glycan attachment site.
Patients and methods
IEF and SDS-PAGE of transferrin
IEF of transferrin was performed as described in two cases.
Case 1 was suspected of CDG due to a clinical presentation
of cyclic vomiting accompanied with ketosis and metabolic
acidosis and the appearance of atypical fat pads and
inverted nipples at the age of seven. Hemoglobin and mean
corpuscular volume were normal. Case 2 was a healthy
donor for blood transfusion, who participated in a large-
scale screening for transferrin variants in populations of
Japan and New Zealand (Yuasa et al. 1987). His mother
was also healthy.
Five μL of plasma was incubated for 30 min with
equal volumes of 6.7 mM Fe(III)citrate and 0.17 mM
NaHCO3 (Fluka, Buchs, Switzerland) in ultrapure water,
then diluted ten times in saline. Two μL of each sample
was transferred to a hydrated immobilin dry gel (GE
Healthcare, Buckinghamshire, UK) with Servalyt, pH 5–7
Fig. 1 Transferrin isoelectric
focusing profiles before and after
neuraminidase incubation. Lane 1
and 1’: control, lane 2 and 2’:
PMM2-CDG, lane 3 and 3’:c a s e
1, lane 4 and 4’:m o t h e ro fc a s e1 ,
lane 5 and 5’: case 2, lane 6 and
6’:motherofcase2,lane7and7’:
patient with a known “D variant”
polymorphism. Left and right of
the figure are the numbers of
sialic acids present on transferrin
Cv a r i a n t
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(GE Healthcare). Different isoforms of transferrin were
detected by immunoprecipitation in the gel with 60 μL
rabbit-anti-human transferrin antibody per gel (8.5 g/l; Dako,
Glostrup, Denmark) for 30 min, followed by overnight
washing in saline, fixation with 20% (w/v) trichloracetic acid
and Coomassie blue staining.
Removal of sialic acids was achieved by incubating 3 μL
of plasma for 30 min with the same volume of 6.7 mM Fe(III)
citrate and 0.17 mM NaHCO3 (Fluka) in water, prior to
addition of 15 mU of neuraminidase (Roche diagnostics,
Mannheim, Germany) and incubation for two hours at 37°C.
IEF was then performed identically to non-treated samples.
Prior to SDS-PAGE analysis, plasma samples were
centrifuged and diluted 100-fold with ultrapure water.
Three μL diluted sample was mixed with 100 μL sample
buffer (10 mM Tris–HCl, pH 8.0, 1 mM EDTA, 2.5% SDS,
2% DTT, and 0.01% bromophenol blue) and heated for
5 min at 95°C. The samples were then applied to a 12.5%
Phastgel (GE Healthcare) and the proteins separated on a
Phastsystem (GE Healthcare). After separation, the proteins
were detected by western blotting using a primary rabbit
anti-human transferrin antibody (Dako) and a secondary
goat anti-rabbit peroxidase conjugated antibody, followed
by electrochemiluminescence detection.
Matrix assisted laser desorption/ionization-MS
(MALDI-MS) of transferrin
The purified transferrin was desalted by a ZipTip C4
(Millipore, Bedford, MA) and analysed by MALDI mass
spectrometry using a Voyager DE Pro MALDI-time-of-flight
mass spectrometer with a nitrogen pulsed laser (337 nm)
(Applied Biosystems, Foster City, CA) (Wada et al. 1994).
The sample matrix was 10 mg/mL sinapinic acid in a 0.1%
(v/v) TFA and 30% (v/v) acetonitrile solution. The measure-
ments were carried out in positive ion and linear TOF mode.
For electrospray MS of peptides, transferrin was dis-
solved in a solution of 6 M guanidine, 0.25 M Tris-HCl, pH
8.0, reduced with 0.13 M dithiothreitol at 50°C for 1 h and
then S-carbamidomethylated with 0.22 M iodoacetamide
for 30 min at room temperature. Tryptic peptides were
desalted by ZipTip C18 (Millipore), dissolved in a 0.1%
formic acid and 50% (v/v) acetonitrile solution and were
directly infused into an LTQ XL ion trap mass spectrometer
(Thermo-Fisher Scientific, San Jose, CA) using a nanospray
tip. The CID MS/MS was carried out with helium gas and
the spectra were acquired by 100 scans.
Genetic analysis
DNA from case 1 and his mother was isolated from whole
blood samples by the commonly used salt-out method for
DNA isolation. DNA of other family members was isolated
from archived dried blood spots on filter paper using the
QIAamp DNA Micro Kit (Qiagen, Valencia, CA). The
isolation process was performed according to the recom-
mended manufacturer protocols. The primers were designed
to the intronic regions surrounding the 17 protein coding
exons of the transferrin gene (TF gene: OMIM 190000;
NCBI gene ID: 7018; NG_013080.1; ENSG00000091513).
Primer sequences are available upon request. The fragments
were amplified using the Combi PPP Master Mix (Top-Bio
s.r.o; Praha, Czech Republic) and purified by gel extraction
using Wizard SV Gel and PCR clean-Up System (Promega,
Madison, WI). All fragments were sequenced on ABI
PRISM 3100-Avant Genetic Analyzer (Applied Biosys-
tems, Carlsbad, CA) using the Big Dye Terminator v.3.1
Cycle Sequencing Kit (Applied Biosystems) according the
recommended manufacturer protocols. Sequence analyses
were performed using SeqScape Software v2.5 (Applied
Biosystems). The nucleotide numbering follows cDNA
numbering with +1 corresponding to the A of the ATG
translation codon in the reference sequence. The initiation
codon is codon 1. For restriction analyses of the c.1889A > C
mutation, the HpyCH4IV (New England BioLabs, Ipswich,
MA) restriction endonuclease was used according to the
manufacturer protocols of the enzyme.
Results
Clinical suspicion of CDG in case 1 triggered us to perform
IEF of transferrin, which showed a type I profile (Fig. 1,
lane 3) with increased disialotransferrin and decreased
tetrasialotransferrin. Neuraminidase treatment resulted in a
single band corresponding to asialotransferrin, suggesting
that the double band in the untreated sample was not the
result of a protein variant (Fig. 1, lane 3’). IEF of serum
transferrin from case 2 and his mother showed two major
bands in a 1:1 ratio with one band at the level of
tetrasialotransferrin and one band just below disialotrans-
ferrin (Fig. 1, lanes 5 and 6). After neuraminidase
treatment, two bands were visible at the asialotransferrin
position (Fig. 1, lanes 5’ and 6’). The distance between
these two bands is much smaller than between the bands of
sialylated transferrin.
Additional information was obtained by SDS-PAGE
analysis of transferrin. In controls, transferrin SDS-PAGE
shows a single band around 79 kDa corresponding to the
glycoprotein with two N-glycans (Fig. 2). The transferrin of
a PMM2-CDG (CDG-Ia) patient showed bands with non-
glycosylated transferrin at 75 kDa, transferrin with one N-
glycan at 77 kDa and the fully glycosylated transferrin at
79 kDa (Wada et al. 1994). In cases 1 and 2, two bands of
equal intensity were observed at 77 kDa and 79 kDa. This
J Inherit Metab Dis (2011) 34:901–906 903finding was confirmed by MALDI-MS of whole transferrin
(Wada et al. 1994). Instead of a single peak at 79.6 kDa,
peaks were observed at 77.3 kDa and 79.6 kDa,
corresponding to transferrin with one and two N-glycans,
respectively (Fig. 2).
Despite theseindications for trueCDG-Iprofiles,a number
of clues suggested otherwise. On transferrin IEF, the disialio-
and tetrasialotransferrin bands were present in a 1:1 ratio,
while asialotransferrin was normal (<3%). In CDG-I patients,
suchsevereprofilesarecommonlyassociatedwithanincrease
of asialotransferrin. IEF of thyroxin binding globulin (TBG),
another serum glycoprotein used for screening of CDG,
showed a normal pattern (data not shown). Additionally,
transferrin IEF and SDS-PAGE in serum of the healthy
mothers revealed similar patterns to their children’s( F i g .1,
lanes 4 and 6; Fig. 2). In contrast to the results after
neuraminidase digestion, these findings were indicative of a
protein variant.
In order to obtain more insight into the structure of the
transferrin protein in cases 1 and 2, transferrin was immuno-
purified from serum, trypsinized, and the peptides were
analyzed by mass spectrometry. Glycopeptides, known to be
present in the normal transferrin, were detected. In addition, a
thus-far unreported nonglycosylated peptide was found in
case1 asdoubly charged ion at m/z 1252.1 and triply charged
ion at m/z 835.0. MS/MS analysis revealed the peptide
sequence 622-QQQHLFGSTVTDCSGNFCLFR-
642, corresponding to the non-glycosylated glycopeptide 2
with a heterozygous p.Asn630Thr change (Fig. 3). This
asparagine is the second N-glycosylation site of transferrin
(underlined). In case 2, an unknown doubly charged ion with
m/z 750.4 was found. MS/MS sequencing indicated a p.
Asn432His change in the first glycosylation site: 421-
CGLVPVLAENYHK-433 (Fig. 4).
Thus, in both cases, MS/MS analysis of transferrin
peptides showed a heterozygous amino acid change in one
of the N-glycan attachment sites, resulting in a transferrin
molecule with a single N-glycan. As a result, the mutated
transferrin will lack two sialic acids and therefore be
located at the disialotransferrin level on IEF. The imidazole
group of the histidine in case 2 causes a slight pI difference
between the common disialotransferrin and the mutated
form.
For case 1, sequencing of the TF gene revealed the
heterozygous c.1889A > C mutation, thereby confirming
the p.Asn630Thr alteration at the amino acid level. RFLP
analysis in family members of case 1 showed the
heterozygous mutation in the mother of case 1, her sister
and the grandmother. This p.Asn630Thr mutation was not
found in 130 controls.
Case 2 was not available for further investigations at the
molecular level. Yet, based on the amino acid sequence, a
c.1294A > C mutation may have occurred, resulting in the
substitution from Asn (AAT) to His (CAT).
Discussion
In the diagnosis of CDG, it is important to exclude
secondary causes of hypoglycosylation of transferrin, as
well as transferrin variants which show an IEF pattern
suggestive of CDG. In this study, we showed that the
current method to identify a protein variants by treatment of
serum samples with neuraminidase can be misleading when
the mutation is located in one of the amino acids of the
consensus sequence of N-glycosylation for transferrin. The
loss of the N-glycan in half of the transferrin proteins in
serum resulted in a pattern with equal amounts of disialo-
and tetrasialotransferrin. Although this resembles a CDG
type I pattern, the approximate 1:1 ratio between the two
isoforms in combination with low levels of asialotransferrin
(<3%), should trigger one to consider a mutation in one of
the glycosylation sites. If neuraminidase treatment is
inconclusive, IEF of another glycoprotein, like TBG, may
provide additional information about a generalized glyco-
sylation defect. When serum of the patient’s parents is
Fig. 2 MALDI-TOF profile
of immunopurified transferrin,
carrying 1 (m/z 77.3 kDa) or 2
(m/z 79.6 kDa) N-glycan chains.
Dotted line: control, continuous
line: case 1. The gray boxes
represent the glycosylation
consensus sequences of the
transferrin protein. Right:
SDS-PAGE of serum transferrin:
C = control, C1 = case 1,
C1.M. = mother of case 1
904 J Inherit Metab Dis (2011) 34:901–906available, IEF of transferrin in these samples can also help
to exclude such a mutation.
Currently, mass spectrometry is increasingly used in
diagnostics of inborn errors of metabolism. For CDG
diagnosis, MS opportunities are growing (Lacey et al. 2001;
Wada 2007; Guillard et al. 2011). Here, we show that the
application of MS of transferrin (glyco)peptides reveals a
non-glycosylated peptide with a mutated N-glycosylation
consensus sequence Asn-Xxx-Thr/Ser. Alternatively, identifi-
cation of non-glycosylated peptides with normal sequence
Fig. 3 Analysis of transferrin peptides in case 1. a identification
of doubly- and triply charged species, not present in controls.
b MS/MS analysis of m/z 1252.1 indicates a p.N630T mutation
in the second transferrin glycosylation site, thus peptide 622-
QQQHLFGSNVTDCSGNFCLFR-642 is mutated to 622-
QQQHLFGSTVTDCSGNFCLFR-642
Fig. 4 Identification of a
protein mutation in case 2.
MS/MS analysis of m/z 750.4
indicated a p.N432H mutation in
the first transferrin glycosylation
site in case 2, thus peptide
421-CGLVPVLAENYNK-433
is mutated to 421-
CGLVPVLAENYHK-433
J Inherit Metab Dis (2011) 34:901–906 905will direct the diagnostics toward CDG-I. These analyses
do not require additional serum sampling and provide
unambiguous results.
Our findings indicate the potential for mass spectrometric
analysis of transferrin (glyco)peptides, not only in CDG-II,
but also in the diagnostic track of CDG-I patients. It allowed
the detection of two novel mutations in the consensus
glycosylation sites, which influence the screening by trans-
ferrin IEF.
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